+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Patient perspectives and experience with dalfampridine treatment in multiple sclerosis-related walking impairment: the step together program



Patient perspectives and experience with dalfampridine treatment in multiple sclerosis-related walking impairment: the step together program



Patient 8(3): 283-291



Dalfampridine extended-release tablets (dalfampridine-ER; in Europe, prolonged-release fampridine, and elsewhere, fampridine modified or fampridine sustained release), 10 mg twice daily, are available for the treatment of improvement of walking in patients with multiple sclerosis, as demonstrated by an increase in walking speed. On-drug patient perspectives and experiences are valuable to understand and manage this patient population. The objective of this study was to examine perspectives and experiences of patients receiving dalfampridine-ER in a real-world setting. Step Together, an ongoing program that captures real-world patient experience with dalfampridine-ER treatment, consists of a survey administered at baseline (before dalfampridine-ER initiation) and at 30 (first follow-up) and 60 days (second follow-up) after initiation. The survey includes modified versions of the 12-item Multiple Sclerosis Walking Scale (mMSWS-12) and the Sheehan Disability Scale (mSDS) to assess walking ability and functional impairment, respectively. As of September 2013, 2,248 patients participated in the baseline survey and 522 completed both follow-up surveys (completers). Among the completers, improvements in walking ability and function relative to baseline were significant at both follow-ups as measured by mMSWS-12 and mSDS scores, respectively. Notably, 69-74 % of completers at both follow-ups had improved mMSWS-12 scores, with scores greater than the range considered to be minimally clinically significant. Patients who completed the program expressed satisfaction with overall dalfampridine-ER treatment, and 69 % indicated that the survey would help them communicate better with their healthcare providers. Results highlight the utility of patient-reported outcomes in the assessment of patient perspective and experience, providing a useful supplement to traditional objective measures used in clinical studies.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058512911

Download citation: RISBibTeXText

PMID: 25475652

DOI: 10.1007/s40271-014-0102-z


Related references

Treatment of walking impairment in multiple sclerosis with dalfampridine. Therapeutic Advances in Neurological Disorders 4(2): 99-109, 2011

Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment. Therapeutic Advances in Neurological Disorders 5(4): 199-204, 2012

Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis. Annals of the New York Academy of Sciences 1329: 33-44, 2015

Walking impairment in patients with multiple sclerosis - a new therapeutic approach and clinical potential of dalfampridine extended release tablets. Degenerative Neurological and Neuromuscular Disease 2: 53-64, 2019

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials. Multiple Sclerosis 21(10): 1322-1331, 2016

Dalfampridine for the treatment of ambulatory impairment in multiple sclerosis. Future Neurology 5(5): 637-643, 2010

Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Current Medical Research and Opinion 27(7): 1415-1423, 2011

Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study. Multiple Sclerosis 20(6): 733-738, 2015

Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis. International Journal of Ms Care 17(6): 275-283, 2015

Understanding walking activity in multiple sclerosis: step count, walking intensity and uninterrupted walking activity duration related to degree of disability. Neurological Sciences 37(9): 1483-1490, 2017

Dalfampridine: a medication to improve walking in patients with multiple sclerosis. Annals of PharmacoTherapy 46(7-8): 1010-1015, 2012

Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners. Patient 4(3): 189-201, 2011

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis. Neuropsychiatric Disease and Treatment 7: 229-239, 2011

Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis. Core Evidence 5: 107-112, 2010

Status epilepticus associated with dalfampridine in a patient with multiple sclerosis. Journal of Neuropsychiatry and Clinical Neurosciences 24(4): E47-E48, 2013